

Syrian Arab Republic

Tuberculosis profile

Population 2016

18 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.023 (0.022–0.023)	0.12 (0.12–0.13)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0 (0–0.01)
Incidence (includes HIV+TB)	3.8 (2.9–4.8)	21 (16–26)
Incidence (HIV+TB only)	<0.01 (<0.01–<0.01)	0.02 (0.01–0.03)
Incidence (MDR/RR-TB)**	0.37 (0.23–0.51)	2 (1.2–2.8)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	0.2 (0.15–0.25)	1.2 (0.93–1.6)	1.4 (1.1–1.8)
Males	0.22 (0.17–0.28)	2.2 (1.6–2.7)	2.4 (1.8–3)
Total	0.42 (0.31–0.52)	3.4 (2.6–4.3)	3.8 (2.9–4.8)

TB case notifications, 2016

Total cases notified	3 154
Total new and relapse	3 064
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	1%
- % pulmonary	53%
- % bacteriologically confirmed among pulmonary	76%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	80% (63–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.01 (0–0.01)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	1	2%
- on antiretroviral therapy	1	100%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			160 (110–210)
Estimated % of TB cases with MDR/RR-TB	8% (4.9–11)	24% (16–35)	
% notified tested for rifampicin resistance	0%	47%	82
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 23, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 14, XDR-TB: 9	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	91%	2 908
Previously treated cases, excluding relapse, registered in 2015	48%	84
HIV-positive TB cases registered in 2015		0
MDR/RR-TB cases started on second-line treatment in 2014	42%	12
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	15% (14–17)

TB financing, 2017

National TB budget (US\$ millions)


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically